Short answer · Medically reviewed summary · Last updated: 2026-04-06
Aniridia is primarily caused by mutations in the PAX6 gene, which acts as a master regulator for the development of the eyes, brain, and central nervous system. The Genetic Foundation of Aniridia In approximately 90% of cases, Aniridia is caused by a heterozygous mutation in the PAX6 gene located on chromosome 11p13. Think of the PAX6 gene as the "architect’s blueprint" for eye formation; when this blueprint is damaged or missing, the iris fails to develop properly.
5 people with Aniridia have shared their first-person experience on this question at DiseaseMaps.
Which are the causes of Aniridia?
Causes of Aniridia explained: genetic and environmental factors, reviewed against medical sources, plus patient perspectives.
Aniridia is primarily caused by mutations in the PAX6 gene, which acts as a master regulator for the development of the eyes, brain, and central nervous system.
The Genetic Foundation of Aniridia
In approximately 90% of cases, Aniridia is caused by a heterozygous mutation in the PAX6 gene located on chromosome 11p13. Think of the PAX6 gene as the "architect’s blueprint" for eye formation; when this blueprint is damaged or missing, the iris fails to develop properly. While most cases are inherited in an autosomal dominant pattern—meaning a child has a 50% chance of inheriting the condition from an affected parent—about one-third of cases arise from de novo (spontaneous) mutations, occurring for the first time in an individual with no family history of Aniridia.
Understanding Etiology vs. Risk Factors
It is important to distinguish between the direct cause and potential complications. The cause of Aniridia is strictly genetic; there are no known environmental triggers, autoimmune processes, or metabolic mechanisms that cause the condition itself. However, clinical researchers often distinguish between the primary genetic defect and secondary "risk factors" that exacerbate visual outcomes, such as the development of glaucoma or keratopathy, which are common secondary features of Aniridia.
Current Research Directions
While the role of PAX6 is well-established, medical researchers are currently investigating the "dosage sensitivity" of the gene—why some individuals with the same mutation experience widely different clinical severities. Modern research is also exploring gene therapy and small-molecule read-through agents designed to "fix" stop-codon mutations in the PAX6 sequence. By studying the underlying molecular pathways of Aniridia, scientists hope to develop targeted therapies that could one day preserve or restore visual function in patients living with this condition.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Aniridia
- Orphanet: Congenital Aniridia
- OMIM (Online Mendelian Inheritance in Man): PAX6 Gene Overview
Posted Mar 5, 2017 by James 1205
Posted Mar 23, 2017 by KATHERINE HASLAM 1000
pax 6 gene 11 chromosome
Posted Jan 30, 2019 by Rachel and Scarlett 1400
Posted Jun 3, 2019 by Mad-Eye Louie 1260
Posted Sep 16, 2017 by Loana 1701
